{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:58:23Z","timestamp":1787979503255,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12185-023-03670-3","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:01:52Z","timestamp":1698296512000},"page":"682-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia"],"prefix":"10.1007","volume":"118","author":[{"given":"Lauren T.","family":"Shinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia L.","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn M.","family":"Buhlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte B.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Zacholski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Stump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor M.","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-8948","authenticated-orcid":false,"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"3670_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fonc.2018.00587","volume":"8","author":"M Medinger","year":"2018","unstructured":"Medinger M, Drexler B, Lengerke C, Passweg J. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment. Front Oncol. 2018;8:587.","journal-title":"Front Oncol"},{"key":"3670_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","volume":"18","author":"SA Peslak","year":"2017","unstructured":"Peslak SA, Olson T, Babushok DV. Diagnosis and treatment of aplastic anemia. Curr Treat Options Oncol. 2017;18:70.","journal-title":"Curr Treat Options Oncol"},{"key":"3670_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643\u201356.","journal-title":"N Engl J Med"},{"key":"3670_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2015","unstructured":"Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2015;172:187\u2013207.","journal-title":"Br J Haematol"},{"key":"3670_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2002-04-1134","volume":"101","author":"N Frickenhofen","year":"2003","unstructured":"Frickenhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236\u201342.","journal-title":"Blood"},{"key":"3670_CR6","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","volume":"117","author":"A Tichelli","year":"2011","unstructured":"Tichelli A, Schrezenmeier H, Soci\u00e9 G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117:4434\u201341.","journal-title":"Blood"},{"key":"3670_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","volume":"289","author":"S Rosenfeld","year":"2003","unstructured":"Rosenfeld S, Vollmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia. JAMA. 2003;289:1130\u20135.","journal-title":"JAMA"},{"key":"3670_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3324\/haematol.13829","volume":"94","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94:348\u201354.","journal-title":"Haematologica"},{"key":"3670_CR9","unstructured":"Promacta. Package insert. Novartis Pharmaceuticals Corporation; 2021."},{"key":"3670_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540\u201350.","journal-title":"N Engl J Med"},{"key":"3670_CR11","doi-asserted-by":"publisher","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al.  Eltrombopag added to immunosuppression in severe aplastic anemia N Engl J Med. 2022;386:11\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2109965.","DOI":"10.1056\/NEJMoa2109965"},{"key":"3670_CR12","doi-asserted-by":"crossref","unstructured":"Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica 2021 [Online ahead of print].","DOI":"10.3324\/haematol.2021.278413"},{"key":"3670_CR13","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1182\/blood.V126.23.4779.4779","volume":"126","author":"T Kadia","year":"2015","unstructured":"Kadia T, Ravandi F, Daver N, et al. Single-center experience of immunosuppressive therapy with or without eltrombopag in patients with aplastic anemia. Blood. 2015;126:4779.","journal-title":"Blood"},{"key":"3670_CR14","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1002\/cncr.31658","volume":"124","author":"R Assi","year":"2018","unstructured":"Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124:4192\u2013201.","journal-title":"Cancer"},{"key":"3670_CR15","doi-asserted-by":"crossref","unstructured":"Fang M, Song H, Zhang J, Li S, Shen D, Tang Y. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: a Chinese retrospective study. Pediatr Hematol Oncol J 2021 [Online ahead of print].","DOI":"10.1080\/08880018.2021.1895924"},{"key":"3670_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29066","volume":"68","author":"H Lesmana","year":"2021","unstructured":"Lesmana H, Jacobs T, Boals M, et al. Eltrombopag in children with severe aplastic anemia. Pediatr Blood Cancer. 2021;68: e29066.","journal-title":"Pediatr Blood Cancer"},{"key":"3670_CR17","doi-asserted-by":"crossref","unstructured":"Jie M, Fu L, Li S, et al. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. Pediatr Hematol Oncol J 2021 [Online ahead of print].","DOI":"10.1080\/08880018.2021.1900475"},{"key":"3670_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10245332.2017.1422306","volume":"23","author":"Y Hwang","year":"2018","unstructured":"Hwang Y, Gill H, Chan TSY, et al. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting. Hematol. 2018;23:399\u2013404.","journal-title":"Hematol"},{"key":"3670_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.24897","volume":"92","author":"P Boddu","year":"2017","unstructured":"Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: a single institution experience. Am J Hematol. 2017;92:1295\u2013302.","journal-title":"Am J Hematol"},{"key":"3670_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2169\/internalmedicine.6063-20","volume":"60","author":"K Imada","year":"2021","unstructured":"Imada K, Obara N, Iida H, et al. Eltrombopag in combination with rabbit anti-thymocyte globulin\/cyclosporine A in immunosuppressive therapy-na\u00efve patients with aplastic anemia in Japan. Intern Med. 2021;60:1159\u201368. https:\/\/doi.org\/10.2169\/internalmedicine.6063-20.","journal-title":"Intern Med"},{"key":"3670_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjh.17232","volume":"192","author":"EM Groarke","year":"2021","unstructured":"Groarke EM, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anemia. Br J Haematol. 2021;192:605\u201314.","journal-title":"Br J Haematol"},{"key":"3670_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1365-2141.2008.07389.x","volume":"143","author":"SY Kao","year":"2008","unstructured":"Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (>60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol. 2008;143:738\u201343.","journal-title":"Br J Haematol"},{"key":"3670_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute: Division of Cancer Treatment & Diagnosis;2018. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed June 11, 2022."},{"key":"3670_CR24","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428\u201336.","journal-title":"Blood"},{"key":"3670_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.imlet.2014.06.016","volume":"162","author":"T Pritz","year":"2014","unstructured":"Pritz T, Weinberger B, Grubeck-Lobenstein B. The aging bone marrow and its impact on immune responses in old age. Immunol Lett. 2014;162:310\u20135.","journal-title":"Immunol Lett"},{"key":"3670_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3324\/haematol.2021.278413","volume":"107","author":"Y Zaimoku","year":"2022","unstructured":"Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica. 2022;107:126\u201333.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03670-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T15:13:34Z","timestamp":1700838814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03670-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3670"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03670-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dylan Barth accepted a position with AbbVie, Inc. and Taylor Weis with Blueprint Medicines after data collection and analysis. All other authors report no relevant competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}